Atossa Therapeutics (NASDAQ:ATOS) Stock, Quote.Headers.trade-ideas

Atossa Therapeutics

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Redcliffe,,Queensland,,Australia,-,May,14,2018:,Domino's,Pizza,Store

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ATOS

KRYS

PLAY

SUPN

Domino&#39;s Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday

Screenshot 2024-04-01 at 9.57.34 PM

Biotech

General

This Biotech Works On All Phases Of Breast Cancer, From Prevention To Post Surgery

This Drug Developer Is Dedicated To “Transforming The Breast Cancer Paradigm”

Penny Stocks

Interview

Dr. Steven Quay MD, PhD, President &amp; CEO of Atossa Therapeutics Inc. (NASDAQ: ATOS) was recently interviewed by Benzinga.

This Drug Developer Is Dedicated To &#34;Transforming The Breast Cancer Paradigm&#34;

Atossa Therapeutics Inc

Atos SE

ATOS ORIGIN SA UNSP/ADR by Atos Origin SA

On Wednesday, Betsey Stevenson expressed her astonishment at Donald Trump&#8217;s running mate J.D. Vance and his supporters&#8217; economic optimism despite the Federal Reserve&#8217;s <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">recent rate cut. </a>
What Happened: Stevenson, a former Obama administration economic advisor, shared her views on X, stating, &#8220;I have to admit that I am pleasantly surprised that J.D. Vance and his supporters thinks the economy is too strong for the rate cut.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I have to admit that I am pleasantly surprised that JD Vance and his supporters thinks the economy is too strong for the rate cut. <a href="https://t.co/UzHUaHfkJg">https://t.co/UzHUaHfkJg</a>
&mdash; Betsey Stevenson (@BetseyStevenson) <a href="https://twitter.com/BetseyStevenson/status/1836511962118992076?ref_src=twsrc%5Etfw">September 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Stevenson shared a video featuring a Vance rally where he was asked a question on Federal Reserve&#8217;s move to slash interest rates by 50 basis points. The crowd booed when the question was asked.
Vance said, &#8220;My reaction is half a point is nothing compared to what American families have been dealing with for the last 3 years.&#8221; In response to the Vice Presidential candidate&#8217;s answer, the crowd cheered.
See Also: <a href="https://www.benzinga.com/markets/equities/24/09/40895240/wall-street-could-head-higher-as-traders-look-forward-to-retail-sales-data-ahead-of-fed-decision?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nasdaq, S&amp;P 500 Futures Firm Up Ahead Of Retail Sales Data</a>
Why It Matters: Stevenson&#8217;s post is particularly noteworthy given the ongoing debate around the implications of the rate cut. Republican presidential nominee Trump has <a href="https://www.benzinga.com/news/24/09/40931251/trump-isnt-happy-with-jerome-powells-50-bps-rate-cut-maneuver-i-guess-it-shows-the-economy-is-very-b">expressed skepticism</a> over the Federal Reserve's decision, suggesting it could be indicative of a faltering U.S. economy or a politically motivated action.
Stevenson&#8217;s surprise at Vance&#8217;s optimism might stem from her previous criticism of the Republican vice presidential nominee. She had earlier <a href="https://www.benzinga.com/news/24/08/40643613/jd-vance-slammed-by-ex-obama-advisor-for-spewing-frustrating-lies-on-tariffs-stresses-need-for-fact">rebuked Vance</a> for spreading misinformation about the effects of tariffs on consumer prices.
This comment comes in the wake of the Federal Reserve&#8217;s unexpected decision to slash interest rates by 50 basis points, marking the first rate cut in over four years. This move surprised Wall Street analysts who had anticipated a more modest 25-basis-point cut.
Image via Shutterstock
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

Economics

Obama-Era Economist Says She Is 'Pleasantly Surprised' That JD Vance Thinks The 'Economy Is Too Strong For The Rate Cut'

The Federal Reserve implemented its first <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40929003/powells-hawkish-tone-tempers-market-excitement-after-historic-50-basis-point-intere">rate cut since March 2020</a>. The move aimed to combat inflation and economic concerns.
What Happened: The rate cut was widely anticipated, with an 85% likelihood leading up to the announcement. This anticipation led to a bullish reaction in both cryptocurrency and traditional equity markets. However, prices quickly reversed as traders executed buy orders.
Santiment <a href="https://insights.santiment.net/read/rate-cut-celebrations-are-likely-but-watch-for-retail-traders-ruining-the-party-8119?utm_source=twitter&amp;utm_medium=post&amp;utm_campaign=twitter_rate_cut_celebrations_insight_b_091824/&amp;fpr=twitter">noted</a> that this pattern is familiar, having been observed after events like the Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) merge and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) halving. Traders often become euphoric, expecting prices to soar, only to be surprised by a retracement.
Despite the initial bullish reaction, the market&#8217;s response may not be as straightforward. Traders are advised to monitor sentiment and funding rates closely. Positive sentiment could indicate greed, while negative sentiment might signal a buying opportunity.
Two more rate cuts are expected by the end of 2024, potentially lowering interest rates by 100 basis points heading into 2025, according to the report.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40883274/senator-warren-urges-fed-to-slash-rates-by-0-75-veteran-investor-warns-even-0-5-cut?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elizabeth Warren Urges Fed To Slash Rates By 0.75%; Veteran Investor Warns Even 0.5% Cut Could &#8216;Reduce Trump&#8217;s Chances Of Winning&#8217;</a>
Why It Matters: The Federal Reserve&#8217;s decision to <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40927293/powell-defends-0-5-interest-rate-drop-as-right-thing-for-the-economy-doubles-down">cut interest rates by 50 basis points</a> to a range of 4.75% to 5% marks a significant shift in monetary policy. 
Jerome Powell, the Fed Chair, defended the move, stating it was necessary to support the labor market and prevent economic harm. Powell emphasized the importance of acting preemptively to safeguard the economy, highlighting the Fed&#8217;s cautious, <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40927293/powell-defends-0-5-interest-rate-drop-as-right-thing-for-the-economy-doubles-down">data-driven approach</a>.
The rate cut has <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a">broader implications for consumers</a>, potentially affecting mortgage rates, credit card interest rates, and auto loan rates. This trickle-down effect could influence consumer spending and borrowing behavior. 
Despite the initial market euphoria, Powell&#8217;s cautious remarks on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40929003/powells-hawkish-tone-tempers-market-excitement-after-historic-50-basis-point-intere">future rate path have injected uncertainty</a> into the markets. The Fed&#8217;s dot plot indicates further easing ahead, with additional rate cuts expected in the coming years.
Price Action: Bitcoin is trading at $61,950.10, up 0.32% in the last 24 hours. Year to date, it has gained 40.14%. Meanwhile, Ether is currently priced at $2,357.76, rising 0.92% in the last 24 hours. Year to date, it has increased 0.19%, according to <a href="https://www.benzinga.com/pro/login">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40890194/both-trump-and-harris-hold-undergraduate-degrees-in-economics-says-obama-era-economist-but-there-is?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Both Trump And Harris Hold Undergraduate Degrees In Economics, Says Obama-Era Economist But There Is One Candidate He Favors Over The Other</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Federal Reserve

$BTC

$ETH

Bitcoin And Ethereum Euphoria Built Around Rate Cuts Could Be Ruined By Retail Traders, Says Crypto Data Intelligence Platform

Sen. Bernie Sanders (I-Vt.), expressed his dissatisfaction with Donald Trump&#8217;s approach to the ongoing healthcare crisis in America.
What Happened: On Wednesday, Sanders took to X to voice his concerns about Trump&#8217;s handling of the healthcare crisis. He highlighted the fact that despite Trump&#8217;s four-year term as president, his current plan for addressing the healthcare crisis is inadequate. 
Sanders said, &#8220;We are in the midst of a serious health care crisis — 85 million Americans are uninsured or underinsured. Now he&#8217;s working on &#8216;a concept of a plan&#8217; ?? That&#8217;s not going to cut it.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">.<a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> has been in three political campaigns. He was president for four years. We are in the midst of a serious health care crisis — 85 million Americans are uninsured or underinsured. Now he&#39;s working on &quot;a concept of a plan&quot; ?? That&#39;s not going to cut it. <a href="https://t.co/2aK8C9NSS7">pic.twitter.com/2aK8C9NSS7</a>
&mdash; Bernie Sanders (@BernieSanders) <a href="https://twitter.com/BernieSanders/status/1836549690071912865?ref_src=twsrc%5Etfw">September 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
This post comes in the wake of the <a href="https://www.benzinga.com/news/24/09/40868605/trump-vs-harris-presidential-debate-sanders-on-healthcare-disparity-and-more-this-week-in-politics">presidential debate</a> between Trump and Vice President Kamala Harris.
Sanders shared a video in his post where an NBC anchor asked him about comments Trump made at the debate with Harris in regards to Obamacare. The former president had claimed that he saved The Affordable Care Act.The Vermont senator&#8217;s post was in response to this question.
See Also: <a href="https://www.benzinga.com/news/24/09/40899012/elon-musk-reacts-after-trump-campaign-releases-over-50-examples-of-democrats-rhetoric-that-inspired?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts After Trump Campaign Releases Over 50 Examples of Democrats&#8217; Rhetoric That &#8216;Inspired Assassination Attempt&#8217;</a>
Why It Matters: Sanders has been a <a href="https://www.benzinga.com/news/24/07/39784920/bernie-sanders-getting-sick-in-america-should-not-mean-going-bankrupt-losing-your-home-car-or-life-s">vocal critic</a> of the existing U.S. healthcare system, highlighting the financial burden it places on patients. He has previously stated that &#8220;Getting sick in America should not mean going bankrupt, losing your home, car, or life savings.&#8221;
Moreover, Sanders has pointed out the <a href="https://www.benzinga.com/news/24/09/40784837/bernie-sanders-says-if-youre-poor-in-america-youll-live-10-15-years-less-anybody-else-see-a-problem">disparity in health outcomes</a> between the rich and the poor in America, stating that the poor live significantly shorter lives.
Image via Shutterstock
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Bernie Sanders Is Not Having It When Trump Says He Saved Obamacare: 'That's Not Going To Cut It'

Microsoft Corporation&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) vice chair and president, Brad Smith, has raised concerns about potential foreign interference in the upcoming <a href="https://www.benzinga.com/topic/2024-presidential-election">2024 U.S. presidential election</a>.
What Happened: On Wednesday, during his opening testimony at a Senate Intelligence Committee hearing on <a href="https://www.benzinga.com/general/politics/24/09/40743037/putin-says-russia-backs-harris-and-her-infectious-laugh-for-2024-election-we-will-root-for-her">foreign election interference</a>, Smith warned of &#8220;real and serious&#8221; threats, <a href="https://thehill.com/policy/technology/4887227-microsoft-election-iran-trump-russia-harris/">reported</a> The Hill.
He pointed out that the election has become a battleground for foreign actors, specifically Iran and Russia, against presidential candidates Donald Trump and Kamala Harris respectively.
&#8220;We know that there is a presidential race between Donald Trump and Kamala Harris, but this has also become an election of Iran vs Trump and Russia vs Harris,&#8221; he stated.
See Also: <a href="https://www.benzinga.com/news/24/09/40893054/mark-cuban-says-he-would-buy-rupert-murdochs-fox-news-and-elon-musks-x-but-there-are-some-obstacles?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Says He Would Buy Rupert Murdoch&#8217;s Fox News And Elon Musk&#8217;s X But There Are Some Obstacles: &#8216;If I Had Enough… I&#8217;d Buy It In A Heartbeat&#8217;</a>
Smith also shed light on the <a href="https://www.benzinga.com/news/24/09/40760931/trump-vs-harris-who-do-russia-iran-and-china-favor-in-2024-election-intelligence-officials-weigh-in">combined efforts of Russia, Iran, and China</a> in undermining democracy. He cited a recent Microsoft report that revealed Russian influence operations behind a false <a href="https://www.benzinga.com/news/24/09/40915084/kremlin-aligned-group-behind-false-hit-and-run-allegations-against-kamala-harris-microsoft-says">viral video accusing Harris of a hit-and-run</a>.
He stressed the importance of tech companies upholding two principles: preserving the right to free expression and protecting the American electorate from foreign deception.
Smith called on tech companies to put in place safeguards, especially around AI-generated content, and to educate candidates about AI risks.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: Smith&#8217;s testimony comes at a time when concerns over foreign interference in the election through online disinformation and misinformation campaigns are escalating.
He testified alongside Nick Clegg, the president of global affairs at Meta Platforms, and Kent Walker, the president and chief legal officer for Google's Alphabet, the report noted.
On Tuesday, in a blog post, Microsoft revealed that its Threat Analysis Center noticed a <a href="https://www.benzinga.com/news/24/09/40912191/harris-walz-campaign-targeted-by-russian-hackers-microsoft-threat-analysis-center-notices-shift-in-t">shift in tactics by Russian hackers</a> who targeted the campaign of Democratic nominee Harris.
Earlier this month, the Justice Department seized over 30 web domains used by Russia for covert campaigns. The FBI also revealed that Iran was behind a hacking of the Trump campaign.
On Wednesday, the FBI said, &#8220;Iranian malicious cyber actors in late June and early July sent unsolicited emails to individuals then associated with President Biden's campaign that contained an excerpt taken from stolen, non-public material from former President Trump's campaign as text in the emails.&#8221;
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40914747/jpmorgan-ceo-jamie-dimon-thinks-social-media-platforms-like-tiktok-and-facebook-are-a-total-stupid-w?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">JPMorgan CEO Jamie Dimon Thinks Social Media Platforms Like TikTok And Facebook Are &#8216;A Total Stupid Waste Of Time&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

MSFT

'This Has Also Become An Election Of Iran Vs Trump And Russia Vs Harris' — Microsoft President Brad Smith Warns About Foreign Interference In 2024 Election

In the run-up to the presidential election, Donald Trump, the Republican nominee, has voiced his disapproval of the Federal Reserve&#8217;s recent decision to <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">slash its benchmark interest rate by half a percentage point</a>. Trump suggests this move could be indicative of a faltering U.S. economy or a politically motivated action.
What Happened: Trump expressed skepticism over the Federal Reserve&#8217;s decision. This critique comes as the November presidential election is just around the corner, <a href="https://www.ft.com/content/da9347a5-b4db-4987-94c9-2aeb20624726">reported</a> The Financial Times.
&#8220;I guess it shows the economy is very bad to cut it by that much, assuming that they are not just playing politics,&#8221; said Trump.
Trump has previously voiced his displeasure with Federal chair Jerome Powell, accusing the independent central bank of political bias. In a conversation with Bloomberg News, Trump cautioned Powell against reducing interest rates before the election. However, he also mentioned that he would allow Powell to complete his term as chair if he was &#8220;doing the right thing.&#8221;
In a separate discussion with Fox Business Network, Trump hinted at his intention to replace Powell, blaming him for being &#8220;political&#8221; and predicting he would lower interest rates to &#8220;help the Democrats,&#8221; according to the report.
Trump&#8217;s remarks were made just hours before a campaign rally in the suburbs of New York City on Long Island. His Democratic rival, vice-president Kamala Harris, also reportedly shared her thoughts on the Fed&#8217;s decision, stating the cut would be &#8220;welcome news for Americans who have borne the brunt of high prices&#8221;.
See Also: <a href="https://www.benzinga.com/news/24/09/40890590/chuck-schumer-says-if-government-shutdown-happens-it-will-because-of-republican-poison-pills-the-ame?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Chuck Schumer Says If Government Shutdown Happens It Will Be Because Of &#8216;Republican Poison Pills&#8217; — &#8216;The American People Are Going To Hold Them Responsible&#8217;</a>
Why It Matters: The Federal Reserve&#8217;s decision to cut interest rates by 50 basis points marks the first rate cut in over four years, breaking a streak of 12 consecutive months with rates held steady. This decision came as a surprise to Wall Street analysts who had largely anticipated a more modest 25-basis-point cut.
Earlier this month, Trump had <a href="https://www.benzinga.com/general/politics/24/09/40861372/trump-says-no-federal-rates-cuts-before-2024-election-republican-congress-members-say-the-time-i">expressed his desire</a> for the Federal Reserve to leave rates unchanged ahead of the 2024 presidential election. However, investors and members of Congress were expecting a rate cut.
The anticipation among investors for a 50 basis point interest rate cut was growing, and this expectation could have <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40919701/investors-betting-on-50-basis-point-rate-cut-expert-says-market-pressure-could-sw">influenced the Federal Reserve&#8217;s decision</a>. The market was pricing in a 63% likelihood of a 50 basis point cut, a significant increase from 34% the previous week.
Image via Shutterstock
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Trump Isn't Happy With Jerome Powell's 50 Bps Rate Cut Maneuver: 'I Guess It Shows The Economy Is Very Bad'

Antivaccine advocate and former independent presidential candidate, Robert F. Kennedy Jr., stated that he might be appointed by former President Donald Trump to select leaders for key public health agencies, should the former president win a second term.
What Happened: Kennedy Jr. disclosed this information during a discussion with conservative commentator Tucker Carlson, as reported by <a href="https://thehill.com/homenews/campaign/4887585-rfk-jr-trump-fda-nih-cdc/">The Hill</a> on Wednesday.
He named the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health as agencies he might be involved with. Kennedy made this announcement during a Tuesday stop in Wisconsin on Carlson's live tour.
&#8220;President Trump has asked me specifically to do two things. One, to help unravel the capture of the agencies by corrupt influence. In other words, to drain the swamp. And, you know, I had to say something about President Trump,&#8221; said Kennedy Jr.
In a previous conversation with Carlson, Kennedy mentioned that Trump asked him to be part of his transition team if he secures a second term. However, Trump campaign spokesperson Karoline Leavitt labeled discussions about who will serve in a second Trump administration as &#8220;premature&#8221;.
Earlier this month, Democrats and the public health community voiced their concerns over the potential of Kennedy becoming the Health and Human Services secretary in a second Trump term.
See Also: <a href="https://www.benzinga.com/news/24/09/40890069/donald-trump-jr-doesnt-mince-words-democrat-donor-with-a-kamala-harris-bumper-sticker-on-his-car-tri?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Donald Trump Jr. Doesn&#8217;t Mince Words: &#8216;Democrat Donor With A Kamala Harris Bumper Sticker On His Car Tried To Assassinate My Dad&#8217;</a>
Why It Matters: Kennedy&#8217;s potential role in a second Trump administration has been a <a href="https://www.benzinga.com/news/24/07/39898056/robert-kennedy-jr-eyes-role-in-trumps-administration-amid-endorsement-chatter-report">topic of discussion</a> for some time. According to a Benzinga report from July, Kennedy, then an independent presidential candidate, had talks with Trump about endorsing his campaign and possibly taking up a senior role in his administration.
In August, Kennedy <a href="https://www.benzinga.com/general/politics/24/08/40535286/rfk-jr-suspends-2024-presidential-campaign-endorses-trump-to-block-democrats-from-white-house">suspended his presidential campaign</a> and endorsed Trump. He stated that he didn&#8217;t believe he had a real chance of winning the 2024 election and that his continued presence in the race would result in a Democratic Party victory.
Image via Shutterstock
Did You Know? 
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Robert Kennedy Jr: Trump Wants Him To Help Pick CDC, FDA, and NIH Leaders — 'Unravel The Capture Of Agencies By Corrupt Influence'

Shaquille O'Neal is widely recognized as one of the greatest basketball players, but since retiring from the NBA, he&#8217;s gained significant <a href="https://www.benzinga.com/markets/24/07/39915962/shaquille-oneal-began-building-his-estimated-500-million-portfolio-by-investing-in-this-tech-titan-w?utm_campaign=partner_feed&amp;utm_source=yahooFinance&amp;utm_medium=partner_feed&amp;utm_content=real_estate">respect for his business expertise</a> and chance encounters.
What Happened: During a 2018 appearance on "The Ellen Show," Shaq shared two pivotal investment stories.
First, he recounted his &#8220;worst investment ever&#8221; — turning down Starbucks.&nbsp;
When Starbucks&#8217; then-CEO Howard Schultz proposed opening locations in African-American communities, Shaq&#8217;s response was skeptical. 
&#8220;Black people don&#8217;t drink coffee,&#8221; he said referring to his earlier thought. This misconception led him to pass on what could have been a lucrative opportunity.
"So now, every time I go to Starbucks, I see black people drinking coffee, I&#8217;m like… [he does a facepalm]."
See Also: <a href="https://www.benzinga.com/general/entertainment/24/09/40824404/shaq-once-said-the-earth-was-flat-and-then-it-cost-him-20m-it-was-like-500k-hate-mail">Shaq Once Said The &#8216;Earth Was Flat&#8217; And Then It Cost Him $20M: &#8216;It Was Like 500K Hate Mail&#8217;</a>
In contrast, Shaq then shared his successful Google investment story.
He recalled a chance encounter at the Four Seasons Hotel in LA around &#8217;93 or &#8217;94, where he was essentially babysitting someone&#8217;s kids during a meeting.
After the meeting, the impressed parent offered him an investment opportunity, saying, &#8220;In the future, you&#8217;re going to be able to type on your phone, search engine, this, do this, boom, boom, boom. You should invest.&#8221;
This turned out to be Google, and Shaq's decision to invest paid off handsomely. Google, now rebranded as Alphabet Inc. has a current market cap of $1.973 trillion, making it the fourth most valuable company in the world.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Shaq&#039;s Babysitting Gig Led to His Google Riches" width="500" height="281" src="https://www.youtube.com/embed/hKNRieaN0ZI?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Why It&#8217;s Important: This anecdote highlights how unconventional networking can lead to significant investment opportunities in the tech world.
Shaq's Google investment marked the beginning of his successful post-NBA business career, setting him apart from the <a href="https://www.benzinga.com/general/entertainment/23/02/30945804/google-apple-lyft-and-ring-shaquille-oneals-track-record-of-phenomenal-startup-investments">65% of NBA players</a> who reportedly go broke within five years of leaving the game.
Earlier this month, the website CelebrityNetWorth estimated Shaq&#8217;s net wealth to be around $500 million. His investment portfolio includes stakes in various franchises such as Five Guys, Papa John&#8217;s, Krispy Kreme, and his own fast-food chain, Big Chicken.
Apart from Google, other <a href="https://www.benzinga.com/general/sports/24/04/38090549/7-basketball-legends-turn-investment-titans-shaq-lebron-and-more">notable company investments</a> include Ring video doorbell, which was later acquired by Amazon, and Apple.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40911877/jeff-bezos-had-a-habit-of-keeping-an-empty-chair-for-the-most-important-person-in-the-room-at-compan">Jeff Bezos Had A Habit Of Keeping An Empty Chair For The Most Important Person In The Room At Company Meetings: This Strategy Helped The Amazon Founder Build The E-commerce Giant We Know Today</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

Shaquille O'Neal's Estimated $500M Portfolio Includes A Big Bet On Google, But Big Shamrock Made A Critical Error That Makes Him Facepalm Each Time He Steps Into A Starbucks — 'Worst Investment Ever'

BNZIW

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BNZI

GDHG

Investors now have more ways to invest in or against MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), a software company and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) holder that has outperformed top stocks, asset types and index funds <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39817792/missed-out-on-nvidia-michael-saylor-says-get-on-the-bitcoin-standard-for-even-better-retur">in recent years.</a>
What Happened: REX Shares and Tuttle Capital Management launched two new ETFs Wednesday to give investors more ways to get exposure <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40878741/canaccord-lowers-microstrategy-price-target-to-173-cites-ongoing-bitcoin-accumulation">to MicroStrategy stock </a>with leveraged and inverse ETFs.
The two companies launched the T-REX 2X Long MSTR Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MSTU#BATS">MSTU</a>) and the T-REX 2X Inverse MSTR Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MSTZ#BATS">MSTZ</a>).
"These are the first ETFs to provide investors with 200% leveraged exposure and -200% inverse exposure to the daily price movement of MicroStrategy (MSTR), allowing traders to capitalize on MSTR's exposure to the Bitcoin market," the companies said.
The launch comes after <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40399008/mstx-becomes-first-single-stock-leveraged-etf-for-microstrategy-stock-offers-175-exposure">Defiance launched</a> a 1.75X long MicroStrategy ETF and 1.5X Short MicroStrategy ETF in August with the Defiance Daily Target 1.75X Long MSTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTX#NASDAQ">MSTX</a>) and Defiance Daily Target 1.5X Short MSTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMST#NASDAQ">SMST</a>) respectively.
With the new 2X ETFs, REX and Tuttle have pushed the envelope further.
"The 2X Leveraged and 2X Inverse MSTR ETFs offer traders unparalleled access to MicroStrategy's Bitcoin exposure, whether they're looking to amplify potential gains or hedge against market volatility. We're a product of our ability to redefine what's possible in the ETF industry," Tuttle Capital Management CEO Matthew Tuttle said.
REX Shares CEO Greg King said the new ETFs help provide tools to traders "to engage with a company that's pushing the boundaries in digital assets."
"MicroStrategy's forward-thinking approach presents a compelling opportunity for traders seeking additional ways to trade the stock," King added.
The launches follow several other leveraged and inverse ETFs from REX and Tuttle Capital. The two companies launched the T-REX 2X Long Bitcoin Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BTCL#BATS">BTCL</a>) and T-REX 2X Inverse Bitcoin Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BTCZ#BATS">BTCZ</a>) in July.
Read Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/24/09/40802938/fund-manager-who-bet-against-jim-cramer-and-cathie-wood-has-new-anti-woke-etf-puts-profits-ah">Fund Manager Who Bet Against Jim Cramer And Cathie Wood Has New Anti-Woke ETF: &#8216;Puts Profits Ahead Of Politics, DEI &amp; ESG&#8217;</a>
Why It's Important: MicroStrategy has been a top-performing stock, gaining 94% year-to-date in 2024 and gaining 790% over the last five years.
The company has also seen shares highly volatile as related to the price of Bitcoin because the company is a large holder of the leading cryptocurrency.
MicroStrategy <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40857237/microstrategy-stock-climbs-after-bitcoin-purchase-heres-how-much-btc-michael-saylors-compa">recently announced it bought</a> $1.1 billion worth of Bitcoin bringing its total up to 244,800 Bitcoin. The company <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40919378/microstrategy-raises-875m-in-convertible-notes-plans-further-bitcoin-purchases">recently raised</a> over $800 million to redeem $500 million in senior secured notes and to buy additional Bitcoin.
MicroStrategy began buying Bitcoin in August 2020 and will continue to add more Bitcoin, as co-founder and Executive Chairman Michael Saylor <a href="https://www.benzinga.com/markets/cryptocurrency/22/06/27865236/exclusive-michael-saylors-microstrategy-is-married-to-bitcoin-everything-else-in-the-world">previously told Benzinga.</a>
"We have a simple strategy and our strategy is we just acquire Bitcoin, and we hold the Bitcoin," Saylor told Benzinga.
Saylor said he believes Bitcoin is the best asset in the world.
"Everything else in the world is inferior to Bitcoin. So, if you gave me $1 million and said what do you want to buy, I don't want to buy a sports team, I don't want to buy a building, I don't want to buy a company … all I want to buy is Bitcoin," Saylor previously told Benzinga.
Saylor also previously said that if people hate Bitcoin, they can short MicroStrategy and if they love Bitcoin they could buy the stock.
While investors have more ways to get Bitcoin exposure thanks to cryptocurrency exchanges and Bitcoin ETFs, MicroStrategy remains a popular option to get exposure.
With the new leveraged and inverse ETFs, investors have more ways to predict what will happen to MicroStrategy in terms of the stock going up or down.
Tuttle <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36500461/exclusive-the-man-who-shorts-cathie-wood-and-jim-cramer-filed-for-new-bitcoin-etfs-why-lev">previously told Benzinga</a> that leveraged and inverse ETFs aren't for all investors, but have an important place in the market.
"They are a tool, just like stocks, bonds, ETFs, mutual funds, options, etc.," Tuttle told Benzinga. "Just like any tool some people will use them correctly and others won't."
Tuttle said that leveraged ETFs can be used by investors as an &#8220;alternative to options.&#8221;
&#8220;Unlike options, they can be traded after hours. They are very conducive to short-term trading strategies.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40855829/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo: Master Tux from Pixabay

Specialty ETFs

New ETFs

ETFs

BTCL

BTCZ

MSTR

ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF

MSTU

MSTX

ETF Opportunities Trust T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ

SMST

MicroStrategy 2X Leveraged, Inverse ETFs Are Here, Offer 'Unparalleled Access To MicroStrategy's Bitcoin Exposure'

A well-known Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) analyst and iPhone sales forecaster is predicting weak demand of the iPhone 16 with a new hint that expectations <a href="https://www.benzinga.com/news/24/09/40882969/iphone-16-pro-demand-lags-longer-wait-times-globally-china-shows-smaller-gap-analyst">may not be met.</a>
What Happened: Apple <a href="https://www.benzinga.com/news/24/09/40780100/apple-intelligence-ready-iphone-16-with-faster-processor-dedicated-camera-button-announced-check-pri">unveiled the iPhone 16</a> last week and highlighted several new features including its Apple Intelligence generative AI that will be rolled out to consumers.
Early pre-order data shows demand for the iPhone 16 may be lower than expected due to a lack of reasons for existing iPhone owners to upgrade to the latest model.
Apple analyst Ming-Chi Kuo recently said pre-order sales for the iPhone 16 have reached 37 million units.
On Wednesday, Kuo shared another sign that demand could be low.
"Apple employees can already purchase the iPhone 16 with their employee discount. Typically, employees have had to wait several weeks after the release of new iPhone models before being able to buy. This could be another sign that the early demand for the iPhone 16 is below expectations," Kuo <a href="https://x.com/mingchikuo/status/1836445270902808958">tweeted</a>.
Kuo's recent 37 million estimate comes from pre-order data from Apple and supply chain surveys. Average delivery times and shipment volumes could indicate weaker demand for the more expensive iPhone Pro models, Kuo also said.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
 Why It's Important: Smartphone competition in global markets such as China could be hurting demand for the iPhone 16 along with weak reception to the Glowtime event and the new features.
With many consumers expecting more integrated AI features, the lack of AI features and slow rollout of Apple Intelligence could be a disappointment.
While it remains to be determined what the official sales figures for the iPhone 16 in 2024 and beyond are, initial iPhone 16 leaks aren't suggesting strong results.
Analysts could lower price targets and financial expectations as more data becomes available.
Pre-orders for the iPhone 16 began on Sept. 13 with initial deliveries on Sept. 20.
 AAPL Price Action: Apple stock closed Wednesday up 1.80% at $220.69 versus a 52-week trading range of $164.08 to $237.23. Apple stock is up 18.9% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40799397/apple-analysts-mixed-after-glowtime-event-iphone-16-could-drive-upgrades-but-next-y">Apple Analysts Mixed After Glowtime Event: iPhone 16 Could &#8216;Drive Upgrades,&#8217; But &#8216;Next Year Will Be Better&#8217;</a></li>
</ul>
Photo: Courtesy Apple

AAPL

Apple iPhone 16 Pre-Orders Show Possible Low Demand, One Sign Could Point To Company Break With This Employee Rule

Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) is set to end its work-from-home regime and mandate a return to full-time office work starting in January.&nbsp; CEO Andy Jassy shared the news to employees in a Monday memo, also announcing changes to<a href="https://www.benzinga.com/top-stories/24/09/40887347/amazon-to-cut-management-layers-end-work-from-home"> the managerial structure.</a>
The end of a flexible work-from-home mandate has a more meaningful impact for the average employee. This decision has drawn considerable attention, particularly from former employees such as John McBride, a former Amazon Web Services (AWS) software engineer, who shared his opinions in an<a href="https://x.com/johncodezzz/status/1836259845118231000"> X</a> post.
McBride, who worked at AWS for a year before resigning due to Amazon&#8217;s insistence on relocating from Denver to Seattle, believes the move to reinstate full office presence is primarily driven by economic factors — as headcount reduction helps the company boost its margin.
Amazon hired heavily in the COVID-19 aftershock, adding over 400,000 employees through 2020. McBride believes the company has overhired and since then, has gone through several phases, starting with mass layoffs and gradually implementing stricter office requirements to push employees into resigning if they refuse to relocate.
His former colleague, former AWS senior developer Justin Garrison, documented such a practice as "<a href="https://justingarrison.com/blog/2023-12-30-amazons-silent-sacking/">The Silent Sacking</a>."
Garrison explained that instead of openly laying off employees, Amazon quietly encourages them to leave by making their roles undesirable. Employees are excluded from meetings, given unfulfilling work and generally made to feel unwelcome, pushing them to quit voluntarily.
This method helps Amazon cut costs without formally announcing mass layoffs or offering severance packages. His experiences show a company that quietly subverts its employees, avoiding the public scrutiny of large-scale firings.
While the means offer a reasonably clear explanation, the ends are mixed.
McBride's claim about AWS's thin operating margins is unsubstantiated. That segment has been the most profitable, with margins reaching almost 40%.
Still, his remark on tax breaks and the office presents a more reasonable angle. In 2022, Amazon received<a href="https://qz.com/amazon-s-5-billion-discount-see-all-its-tax-cuts-and-1849821611"> at least $5 billion</a> in U.S.-based tax breaks and other subsidies from 38 states, with $824 million coming from Virginia, where the corporation has a second domestic headquarters.
The company specifically located the second headquarters there, Crystal City, which is part of Arlington, Virginia, after asking for subsidy proposals from state and local governments.
Furthermore, office-based work can positively impact local economies by supporting restaurants, transportation and other services around corporate hubs. This creates a ripple effect that benefits not just Amazon, but the broader business ecosystem in cities like Arlington.
Also Read: • <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40927293/powell-defends-0-5-interest-rate-drop-as-right-thing-for-the-economy-doubles-down">Powell Defends 0.5% Interest Rate Drop As &#8216;Right Thing For The Economy,&#8217; Doubles Down On Fed&#8217;s Cautious, Data-Driven Approach</a>
Photo: Shutterstock

Large Cap

Rumors

Management

AMZN

Amazon Ends Remote Work, Former Employee Asks If This Is The Company's Version Of 'Silent Sacking'

Billionaire investor, entrepreneur and NBA team owner Mark Cuban announced that the 16th season of "Shark Tank" <a href="https://www.benzinga.com/news/23/11/35971715/billionaire-entrepreneur-mark-cuban-set-to-leave-shark-tank-after-season-16-its-time">will be his last.</a>
With a new shark set to join the cast alongside Cuban in the 16th season, could the show be testing his replacement?
What Happened: Cuban has been a staple on "Shark Tank" since the third season and has <a href="https://www.benzinga.com/news/23/11/35988212/mark-cuban-to-exit-shark-tank-reflects-on-his-worst-deal-and-surprise-success-shared-with-benzinga">invested over $20 million</a> in companies over the numerous seasons of the award-winning investing show.
With Cuban's decision to leave, questions remain on how the show that airs on Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) unit ABC will handle future seasons.
On Wednesday, the company announced that Kind Snacks founder Daniel Lubetzky will be joining the show as the first new regular investor in more than a decade, as reported by <a href="https://variety.com/2024/tv/news/shark-tank-kind-snacks-daniel-lubetzky-1236148219/">Variety</a>.
Lubetzky has previously been a guest shark on the show with appearances in Seasons 11 through 15. The billionaire has <a href="https://www.benzinga.com/startups/24/02/37102187/shark-tank-helped-retired-couple-bring-in-over-100-000-in-less-than-24-hours-after-appearing-on-the">invested in companies </a>such as Yellow Leaf Hammocks, FitFighter, Toast-It and HummViewer while on the show.
With Lubetzky as part of the regular list of panelists, it adds a billionaire who Forbes estimates his wealth at $2.3 billion. Cuban has a net worth of $5.7 billion according to Forbes.
Lubetzky <a href="https://www.benzinga.com/m-a/20/11/18428174/a-look-at-mars-latest-acquisition-kind-bars">sold Kind Snacks </a>to Mars in 2020. He now runs the investment company Camino Partners.
"It's an honor to be part of a production that continues to educate, entertain and unite Americans behind the spirit of building together," Lubetzky said.
Lubetzky said he is looking forward to "partnering with entrepreneurs from all walks of life" who are pursuing the American dream.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Lubetzky is set to join the Season 16 panel, which will include the regular rotation of sharks Cuban, Barbara Corcoran, Lori Greiner, Robert Herjavec, Daymond John and Kevin O'Leary. The season will be Cuban's last.
The show, which is produced by Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)-owned MGM Television in association with Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) unit Sony Pictures Television doesn't show plans of slowing down despite Cuban leaving.
According <a href="https://www.nytimes.com/2024/09/18/business/daniel-lubetzky-shark-tank-mark-cuban.html">to </a>the New York Times, Lubetzky signed a multi-season deal, which likely indicates the producers' confidence in the billionaire having a big part in the show in a post-Cuban world.
"Shark Tank" executive director Clay Newbill said Lubetzky is not a direct replacement for Cuban though.
"Personally, I don't think that you can replace Mark Cuban. He's a force on the show," Newbill said.
Four new guest sharks are also being added for Season 16, including venture capitalist Rashaun Williams and Raising Cane's CEO Todd Graves.
Season 16 is set to premiere on ABC on Oct. 18.
Photo: Shutterstock

Entertainment

Media

Sony Group Corporation American Depositary Shares

SONY

Slide Over Mark Cuban, There's A New Shark In The Pool: Could This Billionaire Be His Replacement On 'Shark Tank'?

Thailand has introduced a new cannabis bill to regulate the country&#8217;s booming marijuana industry, marking the latest step in its ongoing efforts to steer cannabis use toward medical and<a href="https://www.benzinga.com/topic/medical-cannabis"> health-related purposes. </a>
This move comes after a series of policy shifts and follows the 2022 decriminalization of the plant, which made Thailand the first country in Asia to take such action.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40492719/thailands-cannabis-prices-drop-amid-oversupply-and-legal-uncertainties-pakistan-senate-reviews-m">Thailand&#8217;s Cannabis Prices Drop Amid Oversupply And Legal Uncertainties</a>
The new draft bill, published earlier this week by the Ministry of Public Health, is seen as a more measured approach than previous proposals, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-09-18/thailand-unveils-new-bill-to-regulate-cannabis-while-keeping-it-legal">reported.</a>
It arrives just days after Prime Minister Paetongtarn Shinawatra's administration took office. The legislation allows cannabis and its extracts to be used for medical treatment and research by state agencies, while also approving its use in herbal remedies, food products, and cosmetics.
<h3 class="wp-block-heading">Softer Stance On Recreational Use</h3>
One key aspect of the bill is its omission of a clause that explicitly outlaws recreational cannabis use, which was part of an earlier draft under former Prime Minister Srettha Thavisin. 
The new version also abandons previous efforts to reclassify cannabis as a "narcotic," a significant shift from the original stance taken by the ruling Pheu Thai Party during last year&#8217;s national elections. 
While Pheu Thai initially vowed to restrict cannabis use to medical purposes over addiction concerns, opposition from the Bhumjaithai Party, a key coalition partner, has resulted in the plant remaining legal.
Despite this more lenient approach, penalties for those who use cannabis outside the bill's defined uses remain steep. 
Under the current draft, individuals caught using cannabis for purposes not specified in the legislation will face fines of up to 60,000 baht (approximately $1,803). Sellers of cannabis products not adhering to the law face even harsher penalties, including a possible one-year jail term, fines of up to 100,000 baht, or both.
<h3 class="wp-block-heading">Impacts On Thailand's Cannabis Boom</h3>
Thailand&#8217;s decriminalization of cannabis in 2022 led to the rapid rise of more than 9,400 cannabis dispensaries across the country, especially in popular tourist destinations and business hubs such as Bangkok. 
With this new bill, the government seeks to bring tighter control over this growing industry, requiring all cannabis growers, sellers and related businesses to apply for licenses or permits. Failure to comply could result in hefty fines or jail terms.
The draft legislation also calls for stricter regulations on the planting, sale, export and import of cannabis. Businesses that produce cannabis-infused goods, such as candies and baked goods, will be required to adhere to the current law, which mandates that these products contain no more than 0.2% THC, the psychoactive compound responsible for cannabis' "high" effect.
The public and industry stakeholders have until September 30 to submit their feedback on the draft legislation. The Ministry of Public Health will review the input and may make changes before presenting the bill to the cabinet. From there, it will head to parliament for approval, where it could still face further debate and revisions.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/09/40832311/inside-the-thai-retreat-with-cannabis-infused-wellness-treatments-that-target-insomnia-and-more">Inside The Thai Retreat With Cannabis-Infused Wellness Treatments That Target Insomnia And More</a></li>
</ul>
Cover image made with AI.

Asia

Cannabis

Thailand's New Cannabis Bill: Stricter Rules, But Marijuana Remains Legal

A significant Ukrainian drone assault on Russia caused an <a href="https://www.benzinga.com/government/24/09/40888451/russia-to-expand-army-for-third-time-since-war-with-ukraine-began-defense-stocks-rtx-northrop-grumma">earthquake-sized eruption</a> at a major arsenal in the Tver region on Wednesday, forcing citizens in the city of Toropets to evacuate, according to reports from war bloggers and some media.
Unverified video and images on social media showed a huge ball of flame rising into the night sky and numerous explosion detonations tearing across a lake about 240 miles west of Moscow, Reuters reported.
NASA satellites registered intense heat sources coming from an area of about five square miles at the site in the early hours. Earthquake monitoring stations picked up the attack as a small earthquake&nbsp;in the area.
&#8220;The enemy hit an ammunition depot in the area of Toropets,&#8221; said Yuri Podolyaka, a Ukrainian-born, pro-Russian military blogger. &#8220;Everything that can burn is already burning there (and exploding).&#8221;
Read Also: <a href="http://US And Allies Worried Amid Reports Of Russia Potentially Sharing Nuclear Secrets With Iran">US And Allies Worried Amid Reports Of Russia Potentially Sharing Nuclear Secrets With Iran</a>
Ukrainian President Volodymyr Zelenskyy, speaking in his nightly video address, praised the attack without mentioning the target.
&#8220;A very important result was achieved last night on Russian territory and such actions weaken the enemy,&#8221; Zelenskyy said. &#8220;I thank everyone involved. Such precision is truly inspiring.&#8221;
A source in Ukraine&#8217;s SBU state security service told Reuters earlier that the drone attack had destroyed&nbsp;a warehouse storing missiles, guided bombs and artillery ammunition.
Igor Rudenya, governor of the Tver region, said Ukrainian drones had been shot down, a fire had broken out and some residents were being evacuated. He did not say what was burning, Reuters reported.
The size of the main blast shown in the unverified social media video was consistent with 200 to 240 tons of high explosives detonating, said George William Herbert of the Middlebury Institute of International Studies at Monterey in California.
Some war bloggers asked how drones could trigger such large blasts at what was thought to be a highly fortified facility.
Price Action: Defense contractors saw gains and losses by the end of Wednesday&#8217;s trading day.
<ul>
<li>General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) slipped 0.44% to $302.52</li>
<li>Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) rose 0.2% to $521.77</li>
<li>TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) declined 0.12% to $1,273.80</li>
</ul>
Exchange-traded funds that hold defense stocks trended up and down.
<ul>
<li>IShares U.S. Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>) rose 0.06%</li>
<li>Invesco Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPA#NYSE">PPA</a>) fell 0.13%</li>
<li>SPDR S&amp;P Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XAR#NYSE">XAR</a>) declined 0.01%</li>
</ul>
Read Now:
<ul>
<li><a href="http://over-30-months-of-war-zelensky">Russia Launches &#8216;One Of The Heaviest Strikes&#8217; On Ukraine In Over 30 Months Of War: Zelensky</a></li>
</ul>
Photo: Shutterstock

Global

iShares Dow Jones US Aerospace & Defense Index Fund

Ukrainian Drone Attack Causes Earth-Rattling Blast In Russia's Tver Region

CTSH

mecwacare, Cognizant Embark On Multi-year Relationship To Launch Digital Transformation Program

This will result in Vistra being the sole owner of its Vistra Vision subsidiary, which includes its zero-carbon nuclear, energy storage, and solar generation assets, as well as its retail business.
The net present value of the purchase price as of&nbsp;Dec. 31, 2024, discounted at a&nbsp;6%&nbsp;interest rate, is&nbsp;$3.085 billion.
The agreement does not impact or change Vistra&#39;s capital allocation priorities. Vistra remains committed to its long-term net leverage target of less than 3x2. Vistra also continues to expect to execute at least&nbsp;$2.25 billion&nbsp;of share repurchases in 2024 and 2025 and at least&nbsp;$1 billion&nbsp;in 20263, as well as pay&nbsp;$300 million&nbsp;in aggregate common dividends in each year 2024-20263.
&nbsp;

Vistra Enters Deal With Nuveen Asset Management And Avenue Capital To Acquire Their Combined 15% Equity Interest In Vistra Vision LLC For Undiscounted Purchase Price Of $3.248B Cash, To Be Paid In Five Installments

BLMZ

BloomZ Gets Nasdaq Notification Letter That It Is Not In Compliance With Minimum Market Value Requirement

Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) shares moved higher Wednesday as markets witnessed the first interest rate cut from the <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">Federal Reserve in four years. </a>
The Details: Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) miner Core Scientific's stock has climbed more than 20% over the past five days, as investors anticipated an interest rate cut. 
The Federal Reserve announced a 50 basis points (bps) cut Wednesday, bringing the federal funds rate down to a range of 4.75%-5% and increasing the appeal of risk assets like stocks and cryptocurrencies. 
Core Scientific shares climbed throughout Wednesday's session and spiked to an intraday high of $12.48  just after the announcement from Fed Chairman Jerome Powell. 
Read Next: <a href="https://www.benzinga.com/news/large-cap/24/09/40910569/nvidia-salesforce-announce-strategic-ai-collaboration-what-to-know">NVIDIA, Salesforce Announce Strategic AI Collaboration: What To Know</a>
Earlier this month, Core Scientific CEO Adam Sullivan shared plans with Bernstein analysts to <a href="https://www.benzinga.com/top-stories/24/09/40800336/core-scientific-aims-for-25-30-billion-valuation-with-ai-data-center-services-bernstein">significantly expand</a> the company's AI data center services, potentially boosting its valuation to a range of $25 billion to $30 billion.&nbsp;
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Core Scientific shares are trading above the stock&#8217;s 50-day moving average of $10.05 and just under its 52-week high of $12.25.&nbsp;
CORZ Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Core Scientific shares ended Wednesday's session up 4.79% at $12.03.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40904271/whats-going-on-with-amazon-stock">What&#8217;s Going On With Amazon Stock?</a></li>
</ul>
Photo: Shutterstock

Movers

Core Scientific, Inc. - Class A Common Stock

CORZ

What Happened With Bitcoin Miner Core Scientific's Stock Today?

Atossa Therapeutics appoints Heather Rees as chief financial officer

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
By now, you&rsquo;re well aware of the dangers of trading <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> with upside. But as a reminder, not only will you find a disclaimer at the tail-end of this article about penny stock dangers, but here&rsquo;s what the U.S. SEC says:



&ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/"></a>Penny stocks&nbsp;may trade infrequently &mdash; which means that it may be difficult to sell penny stock shares once you have them. Because it may also be difficult to find quotations for penny stocks, they may be impossible to accurately price. Investors in penny stock[s] should be prepared for the possibility that they may lose their whole investment.&rdquo;



Sure, penny stocks are attractive at such low prices. But they&rsquo;re also dangerous.



If you understand the risks and want to invest in them anyway, investigate the stocks where insiders are putting their money where their mouth is. After all, if they&rsquo;re putting up their own money, they must have a good deal of confidence in their stock.



Here are three potential penny stock moonshots you may want to consider.



<h2>Aurora Innovation (AUR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/01/car-1600-300x169.jpg" alt="the front wheels of a series of cars in a line"><div>Source: lumen-digital / Shutterstock.com</div></div>The last time I highlighted an opportunity in Aurora Innovation (NASDAQ:<a href="https://investorplace.com/stock-quotes/aur-stock-quote/">AUR</a>), Uber Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/uber-stock-quote/">UBER</a>) had just bought about $75 million worth of the AUR stock. Plus,&nbsp;Volvo Autonomous Solutions just unveiled&nbsp;AB Volvo&rsquo;s&nbsp;(OTCMKTS:<a href="https://investorplace.com/stock-quotes/vlvly-stock-quote/">VLVLY</a>) first-ever production-ready autonomous truck in Las Vegas &mdash; using Aurora Innovation technology.&nbsp;



That was on June 5, as shares of AUR traded at around $2.15. Today, it&rsquo;s up to $2.81, where it&rsquo;s still a long-term buying opportunity. 



Helping, Aurora&rsquo;s involvement with autonomous trucking gives it exposure to a potential <a href="https://www.fortunebusinessinsights.com/autonomous-truck-market-103590#">$76 billion market opportunity</a> by 2032 from $35.51 billion.



Also, while the company didn&rsquo;t report any revenue for its recent quarter, its earnings per share loss of 11 cents was still better than estimates for a loss of 14 cents. Even better, George Soros&rsquo; fund recently picked up about 4.5 million shares of AUR in late March. Jim Simons&rsquo; Renaissance Technologies also picked up 477,900 shares in late March.



<h2>Globalstar (GSAT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/09/gsat1600-300x169.png" alt="In this photo illustration the Globalstar (GSAT) logo seen displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div>We can also look at oversold shares of telecommunications infrastructure company, Globalstar (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/gsat-stock-quote/">GSAT</a>), which currently trades at $1.07. Fueling interest in the stock, director <a href="https://www.investing.com/news/company-news/globalstar-executive-monroe-james-iii-buys-48-million-in-company-stock-93CH-3503747#:~:text=On%20June%2028%2C%202024%2C%20Monroe,known%20as%20XCom%20Labs%2C%20Inc.">James Monroe III bought 4.51 million shares of GSAT</a> for about $4.8 million on July 1.



Helping, Apple (NASDAQ:<a href="https://investorplace.com/stock-quotes/aapl-stock-quote/">AAPL</a>) recently said it would expand the capabilities of satellite messaging on the iPhone. &ldquo;The new iOS 18 update will broaden the availability beyond emergency messaging, and Messages via satellite will be an option when cellular and Wi-Fi connections are not available,&rdquo; according to <a href="https://www.satellitetoday.com/connectivity/2024/06/11/apple-expands-satellite-messaging-capabilities-with-ios-18/">SatelliteToday.com</a>.&nbsp;



That&rsquo;s great news for GSAT considering it partnered with Apple for the satellite connectivity components.&nbsp;Even better, funds such as <a href="https://hedgefollow.com/stocks/GSAT">Jim Simons&rsquo; Renaissance Technologies</a> recently bought 156,430 shares of GSAT. Israel Englander&rsquo;s Millennium Management also bought another 38,230 shares.



With earnings, while its first quarter EPS loss of a penny was just in line with estimates, its revenue of $56.48 million did beat by $1.74 million.&nbsp;



<h2>Atossa Genetics (ATOS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/biopharma-1600-300x169.jpg" alt="a scientist with protective equipment and microscope in a lab, OBSV stock"><div>Source: luchschenF / Shutterstock.com</div></div>The first time I mentioned&nbsp;Atossa Genetics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/atos-stock-quote/">ATOS</a>), it traded at 75 cents on <a href="https://investorplace.com/2023/04/the-3-best-biotech-stocks-under-1-to-buy-for-april/">April 4, 2023</a>. At the moment, it&rsquo;s up to $1.20, and is still an attractive buy as it pivots from support.



The company recently posted encouraging data from a Phase 2 study of its drug (Z)-endoxifen as a neoadjuvant treatment for breast cancer.



As noted by the company, the 40mg EVANGELINE data is &ldquo;extremely encouraging as it shows that (Z)-endoxifen can not only stop ER+ breast cancer from growing, but it can also shrink or eliminate the tumor, as measured by MRI imaging,&rdquo; <a href="https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-and-quantum-leap-healthcare-announce-i-spy-2#:~:text=%E2%80%9CData%20recently%20presented%20at%20the,MRI%20imaging%2C%E2%80%9D%20said%20Dr.">said Dr. Steven Quay, Atossa&rsquo;s President and Chief Executive Officer</a>.



Even better, funds have been aggressively buying ATOS. At the end of March, for example, <a href="https://hedgefollow.com/stocks/ATOS">Israel Englander&rsquo;s Millennium Management</a> increased its stake in ATOS by 2,040%. Ken Griffin&rsquo;s Citadel Advisors increased its stake by nearly 1,280%. Jim Simons&rsquo; Renaissance Technologies increased its stake by about 8% with the addition of 102,100 shares.



<h2></h2>



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, Ian Cooper&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned.&nbsp;The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=quotemedia&amp;utm_medium=referral">Publishing Guidelines</a>.&nbsp;



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/3-penny-stock-moonshots-with-300-upside-potential-by-2025/">3 Penny Stock Moonshots with 300%+ Upside Potential by 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Penny Stock Moonshots with 300%+ Upside Potential by 2025

Executive reshuffles: NIO, Pfizer and Spirit Airlines in focus

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That&rsquo;s because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results.&nbsp;



Thus, these stocks, especially when trading at low prices, have the potential to rapidly increase in value. In such cases, a frenzy can quickly spike the stock, leading to a relatively short-term situation with above-average returns.&nbsp; However, it is important to keep in mind that just as quickly as these stocks rise they can fall as a result of disappointment or regulatory failures.



That said, if investors understand the medical potential of the drug developer they are investing in, the risk can be more palatable. As such, this article will aim to look at three cheap drug developer stocks whose products could rapidly raise their value.



<h2>Scynexis (SCYX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>As far as cheap drug developers go, Scynexis (NASDAQ:<a href="https://investorplace.com/stock-quotes/scyx-stock-quote/">SCYX</a>) didn&rsquo;t always fall into that category. Rather, the company once traded over $100 and today is down 98% since its initial public offering in 2014. There have been several reasons for this between its recalls and deal restructurings with GSK (NYSE:<a href="https://investorplace.com/stock-quotes/gsk-stock-quote/">GSK</a>). Beyond this, its product pipeline tends to fly under the radar for many investors as its focus on anti-fungal treatments is often misunderstood.



Yet, due to the biology of fungi, treating them is an incredibly difficult feat that could be key to reducing mortality in immunocompromised patients and even preventing a future <a href="https://www.medscape.com/viewarticle/could-fungal-infection-cause-future-pandemic-2024a1000a39?form=fpf">pandemic</a>. Its current fungal genus that it focuses on is Candida which has several strains and can present in several regions in the body.&nbsp;



While the company already has two effective treatments co-developed and brought to market with GSK, its current experimental Candida treatment called <a href="https://www.scynexis.com/our-science/pipeline/">SCY-247</a> could be a future catalyst, as it could potentially treat drug-resistant strains of the fungus, which are becoming <a href="https://www.cdc.gov/candidiasis/antimicrobial-resistance/index.html#:~:text=Antimicrobial%2Dresistant%20invasive%20candidiasis%20is,bloodstream%20infection%20in%20the%20U.S.">more common</a>.



<h2>Atai Life Sciences (ATAI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/05/psychedelics-4-300x169.jpg" alt="Mushrooms next to various medical tools; mushrooms in a pill container to represent psychedelic treatments"><div>Source: Shutterstock</div></div>Atai Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/atai-stock-quote/">ATAI</a>) is currently expanding its focus on alternative mental health therapies through an innovative approach to psychedelic compound research. Its pipeline features a range of drugs based on psychedelic substances such as ketamine, psilocybin and <a href="https://www.europeanpharmaceuticalreview.com/news/178880/major-study-on-dmt-shows-promise-for-depression/">DMT</a>. While these compounds are often associated with recreational use, emerging peer-reviewed studies suggest they contain considerable potential for treating mental health disorders.



The company&rsquo;s current flagship drug, COMP360, is currently in Phase-3 clinical trials in collaboration with Compass Pathways (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmps-stock-quote/">CMPS</a>). COMP360 has also shown incredible promise in treating individuals suffering from major depressive disorder who are resistant to other forms of antidepressants. <a href="https://ir.compasspathways.com/node/8326/pdf">Over 30% </a>of drug-resistant patients saw remission during the 12-week trial period, suggesting breakthrough therapy potential.



Given its current trading price at a 93% discount from its initial public offering, Atai Life Sciences is one of those cheap drug developer stocks investors should not pass up. That&rsquo;s because any positive developments regarding its drug candidates could significantly boost the company&rsquo;s value.



<h2>Atossa Therapeutics (ATOS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/biopharma-1600-300x169.jpg" alt="a scientist with protective equipment and microscope in a lab, OBSV stock"><div>Source: luchschenF / Shutterstock.com</div></div>Unlike many biotechnology companies that prioritize developing treatments for existing diseases, Atossa Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/atos-stock-quote/">ATOS</a>) focuses on disease prevention. One of its most promising drugs, <a href="https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-announces-last-patient-last-dose-its-phase-2">Karisma-Endoxifen</a>, finished its most recent round of clinical trials. This innovative drug aims to reduce breast tissue density, thereby lowering the risk of developing cancer.



The results of these trials are expected soon, and a positive outcome could significantly enhance Atossa&rsquo;s stock potential. Additionally, Atossa&rsquo;s dedicated focus on breast cancer provides stability to its stock, as the company channels all its resources into combating this single disease. Alongside its pharmaceutical treatments, the company has also begun supporting a trial for <a href="https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-announces-support-clinical-study-testing-new">artificial intelligence-based diagnosis</a> of breast cancer.



Pair these innovations with a relatively flat and consistent trading pattern, combined with the potential for promising trial results, and Atossa earns a buy rating. Furthermore, its low stock price means a small investment could go a long way.



On the date of publication, Viktor Zarev&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;
<div>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/3-dirt-cheap-drug-developers-with-blockbuster-potential/">3 Dirt-Cheap Drug Developers With Blockbuster Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Dirt-Cheap Drug Developers With Blockbuster Potential

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report), retaining the price target of $6.0...

Atossa Therapeutics: A Promising Buy Amid Anticipated Clinical Breakthroughs

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Atossa Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/atos-stock-quote/">ATOS</a>) just reported results for the second quarter of 2024.<ul><li>Atossa Therapeutics reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -6 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/atos-stock-earnings-atossa-therapeutics-for-q2-of-2024/">ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024

Atossa Therapeutics GAAP EPS of -$0.05 in-line

Atossa Therapeutics (ATOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCart...

Atossa Therapeutics: A Promising Buy in Oncology with Strong Financials and Upcoming Trial Milestones

Atos SE's ($FR:ATO) shares dropped over 3% as of writing today after the company reduced its financial targets through 2027, citing weakened sales ...

Atos Shares Drop on Reduced Financial Targets

AMAT

ASTS

ASXC

ATAI

BABA

BATL

BEEM

BEKE

BLDP

BLUE

CARA

CATX

CMPS

COCP

CSCO

CTRM

ESPR

FOSL

FWRD

GLNG

GOEV

GOLD

GRAB

GSAT

HUYA

JAGX

KNDI

LITE

MDAI

MIRA

MMAT

MNDY

MTEX

NNDM

NVDA

OGEN

OUST

PSFE

RRAC

RYAN

SACH

SAVE

SCYX

SMID

STNE

TAYD

TCEHY

TCRT

VLVLY

VUZI

WKHS

XXII

Press Releases

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Health Care

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Earnings

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Legal

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Atossa Therapeutics

Atossa Therapeutics (ATOS) Forecast

Atossa Therapeutics (NASDAQ:ATOS) Stock, Quote.Headers.trade-ideas